ArticleCancers2025

Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study.

Christian Möhring et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.